This week's Tuesday Nite Rheumatology featured Dr Randy Cron from the University of Alabama - Birmingham as he spoke and took questions on the immunology, immunopathogenesis and treatment of Cytokine Storm Syndrome, especially as they relate to COVID-19 and rheumatic disease patients.
Two current reports from Boston and Wuhan describe cohorts of COVID-19 (+) rheumatic disease patients who generally do well but appear to have a higher risk of pulmonary involvement.
Hydroxychloroquine (HCQ) has dominated the news in recent weeks, because of poor outcomes reported when used in COVID patients.
A current letter in the Annals of Rheumatic Disease details the rheumatic disease patient cohort outcomes from the University of Siena, Italy showing only 2 cases of COVID-19 among 859 patients treated with tsDMARDs and bDMARDs.
Today Lancet reported the results of another retrospective trial showing that hydroxychloroquine or chloroquine, alone or with a macrolide antibioitic, offered no additional benefits to COVID-19 patients, but was associated with higher rates of mortality and arrhythmia.
Lancet has reported COVID outcomes from NewYork-Presbyterian hospitals in NYC during March 2020 showing high rates of hospitalization, ICU admission, mechanical ventilation and death.
This week's Tuesday Nite Rheumatology features presentations and interviews with Drs. Peter Nash and Philip Robinson. Dr. Robinson presents latest data on the Rheum-Covid.org Registry, that he helped establish under the Global Rheumatology Alliance. Dr.
Congratulations!
Years of training and work, all your efforts and overcoming hurdles have culminated in where you are today – on the verge of a new life, a new plan and possibly a new career.
Anakinra was studied in 29 COVID(+) patients with respiratory distress and high inflammatory markers (CRP or ferritin) and compared to non-anakinra patients, those on anakinra had better survival (90% vs.
Hydroxychloroquine is one of many medications frequently used in rheumatology practice.
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
The latest hazardous spinoff to the coronavirus infection is an inflammatory, Kawasaki-like syndrome unique to children or adolescents with COVID-19. Sporadic reports from around the globe of this severe pediatric COVID syndrome have littered the news with brief mentions and little detail.
Links:
Dr. John Cush RheumNow( View Tweet)
Dr. John Cush RheumNow( View Tweet)
Links:
Dr. John Cush RheumNow( View Tweet)
Links:
BCG & COVID: 1) Israeli study shows BCG vaccination during childhood had no protective effect on getting COVID-19 infection later. 2) Bladder cancer pts on BCG therapy who get COVID infection, can safely take IL-6 or IL-1 inhibitors, Just not TNF inhib. https://t.co/TlOj6b8Taf
Dr. John Cush RheumNow( View Tweet)
T. Scott Diesing, M.D. diesing_t( View Tweet)
Links:
Dr. John Cush RheumNow( View Tweet)
Links:
Dr. John Cush RheumNow( View Tweet)
Dr. John Cush RheumNow( View Tweet)
Links:
Dr. John Cush RheumNow( View Tweet)
